Aprepitant: Two doses of 40mg (2ml) Aprepitant. One to be given on the morning of surgery and the second on the morning of post-op day 1
Placebo: Two doses of dextrose syrup (2ml). One to be given on the morning of surgery and the second on the morning of post-op day 1
Study summary
This research trial will measure how useful Aprepitant is in preventing nausea and vomiting in children having surgery to correct scoliosis (curvature of the spine).
Eligibility
Sex
ALL
Min age
8 Years
Max age
19 Years
Healthy volunteers
No
Inclusion Criteria:
* Posterior Spinal Instrumentation and Fusion (PSIF) for idiopathic scoliosis
* The fusion must include at least 6 vertebral levels.
* Children greater than or equal to 8 years old, and less than 19 years old on the day of surgery
* Weight \> 40kg - for ease of pharmacy preparation (PONV dose 1mg per kg to max 40mg)
Exclusion Criteria:
* Patient/ Parent refusal
* Hypersensitivity to Aprepitant or any ingredient in the formulation or oral solution. (previous allergy or adverse reaction to Aprepitant)
* Developmental delay as reported by parents
* Pregnant - Pregnancy test done as standard of care pre-operative
* Severe systemic disease ASA classification III or greater
* Concurrent use of any medication with severe interaction with Aprepitant as outlined in product monograph.
* Neuromuscular or congenital scoliosis
* Inability to take PO medications
Primary outcome measure(s)
Anti-Nausea Rescue Medication — From surgery end-time until discharge, estimated period of up to 10 days Anti-nausea rescue medication administered (yes/no).
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
